MRNA — Moderna, Inc.
$223.37
$-7.98 (-3.45%)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Market Cap
$90.38B
Forward P/E
-54.8x
52-Week Range
N/A
MRNA Price History
Revenue vs. Net Income
$1.9B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$2.1B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-26.6%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.3x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
10.4%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+1.3%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
